CN103520487B - A kind of purposes of pharmaceutical composition - Google Patents
A kind of purposes of pharmaceutical composition Download PDFInfo
- Publication number
- CN103520487B CN103520487B CN201310491415.9A CN201310491415A CN103520487B CN 103520487 B CN103520487 B CN 103520487B CN 201310491415 A CN201310491415 A CN 201310491415A CN 103520487 B CN103520487 B CN 103520487B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- fructus
- endometrium
- pharmaceutical composition
- rhizoma polygonati
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a kind of novelty teabag of pharmaceutical composition in the medicine for the preparation for the treatment of diminished ovarian reserve function and/or promotion Endometrium development being primary raw material with Herba Epimedii, Fructus Ligustri Lucidi, Rhizoma Polygonati Odorati, Semen sojae atricolor, Flos Sophorae, Fructus Mori, Fructus Rubi, Radix Panacis Quinquefolii, Colla Corii Asini and Paecilomyces hepiali Chen et Dai Mycelia powder.Aforementioned pharmaceutical compositions can be used for increasing Ovary reserve, and promotes Endometrium development by improving gynecological endocrine function and increasing endometrium thickness, has wide potential applicability in clinical practice.
Description
Technical field
The present invention relates to medical art, particularly relate to the application of a kind of pharmaceutical composition in the medicine for the preparation for the treatment of diminished ovarian reserve function and/or promotion Endometrium development.
Background technology
Diminished ovarian reserve function is the transition stage of premature ovarian failure, refers to that ovary produces the reduced capability of ovum, follicle Quality Down, causes the disease of the decline of female fertility ability and sex hormone deficiency, is also called " ovarian senescence ".Clinical manifestation is Hypomenorrhea, and hypomenorrhea, even amenorrhea are infertile, with perimenopausal symptom in various degree, as hectic fever, hyperhidrosis, flush, emotional instability, hyposexuality, vaginal dryness, osteoporosis etc.If can not correct in time, likely develop into premature ovarian failure, be the process of a gradual change from diminished ovarian reserve function to premature ovarian failure, studies have reported that and approximately need 6 months ~ 6 years.
Along with the change of the development, cultural concept, living environment, operating pressure etc. of society, diminished ovarian reserve function sickness rate is increased year by year.There is the healthy reproduction of fertility forfeiture and the own serious threat women of low estrogen level earlier, too increase the danger that women suffers from osteoporosis and coronary heart disease simultaneously.Prisoner this, early treatment's outbalance that Ovary reserve is low.
In prior art, for the treatment of diminished ovarian reserve function, the most frequently used, effective method is hormone Replacement Therapy.Clinical studies show, hormone Replacement Therapy can make patient occur cyclic menses, improves subjects reproductive atrophy and perimenopausal symptom, reduces osteoporotic generation, and its short term effect is obvious, but late result is undesirable; And chronicity swashs the sickness rate that rope replacement therapy obviously can increase the disease such as carcinoma of endometrium, breast carcinoma.Therefore, safer, the effective method improving Ovary reserve is found just by clinician is expected.
Chinese medicine is according to " kidney storing essence ", " kidney governing reproduction ", " the kidney being the origin of congenital constitution " scheduling theory, think that ovary stores up each function reduction pathogenesis and belongs to traditional Chinese medical science deficiency of kidney-essence, deficiency of kidney yin, give the Therapeutic Method of replenishing essence the kidney invigorating, nourishing YIN and benefiting blood, Ovary reserve can be improved significantly, promote the recovery of menstruation, then menstrual blood volume is increased, the infertile person of part is become pregnant, improve the perimenopausal symptom such as hectic fever, hyperhidrosis, its late result is reliable, and treatment by Chinese herbs is safe and effective, therefore Chinese medicine Ovary reserve is adopted lowly to have important clinical value.
Endometrium is thin is women's common disease, and women is having under certain estrogenic effect, and the thickness that when doing ultrasonic examination, endometrium can not reach 8 millimeters is just judged as that endometrium is thin.The reason causing endometrium thin has general, common reason has that estrogen level is low, progesterone level is not enough and there is ovulation failure and lack growth hormone etc., also the reason of local is had, such as inner film injury, adhesion and lack as etc., some patient is after artificial abortion, and endometrium is not yet recovered, and endometrium also can be caused thin.Endometrium is thin will affect germ cell implantation, thus causes infertile, therefore, if find the little treatment means of good effect side effect will bring glad tidings for a large amount of infertile patient.
At present the therapeutic modality that endometrium is thin is mainly contained following several:
(1) estrogen
The first-selected Therapeutic Method of doctor trained in Western medicine aspect is complementing estrogen.Research display overlength estrogen is had to supplement the pregnancy rate that (extended estrogen supplementation) can improve the failed thin women of endometrium of IVF-ET many plantations; But another about endometrium thin women's ICSI estrogen supplement effectiveness study result display, start hCG day estrogen supplement Clinical Pregnancy Rate in, survival rate of embryonic, abortion ratio, endometrium thickness are not all improved.The curative effect of estrogen to the thin patient of some hypoergia endometrium needs to be observed further as can be seen here.
(2) low-dosage aspirin
Aspirin is on the impact of uterine blood flow: low-dosage aspirin increases uterine blood supply by regulating TXA2/PGI2 balance, impels inner membrance to grow, and improves the Endometrium development that clomifene causes bad, improves endometrial state of holding.Also experiment is had to prove, low-dosage aspirin does not affect endometrium thickness, just it increases expression intensity and the MVD(Microvascular density angle value of endometrium Integrin β_3 (it is likely the reason causing thin temper Endometrium angiogenesis obstacle that Integrin β_3 expresses decline), microvascular density) level, then endometrial endometrial receptivity is increased, improve Embryo Implantation Rate in, and non-increasing endometrium thickness.
(3) viagra
'Xiduofeng ' (sildenam), trade name viagra (viagra), it is nitric oxide sample medicine, it improves the cyclic guanosine monophosphate in tissue by the activity of suppression PDE, act on uterine smooth muscle and uterine artery smooth muscle, improve endometrial blood supply, promote endometrial growth, improve endometrium receptivity.There is research display, by oral or vaginal application viagra, the effect improved endometrium thickness and increase Clinical Pregnancy Rate in can be reached; But there is the clinical effectiveness of investigation and comparison viagra oral medication and these two kinds of occupation modes of vagina medicinal, result display vagina medicinal group (7/20) is higher than the cycle pregnancy rate of oral medication group (0/20), but the endometrium thickness zero difference before and after two groups of medications.Therefore, the effect of viagra increase endometrium thickness still needs further research.
(4) pentoxifylline
Methylxanthine derivatives pentoxifylline (PTX) is a kind of phosphodiesterase inhibitor, suppresses phosphodiesterase to the decomposition of cAMP, make to keep in cell high concentration cAMP and to the generation of cytokine and effect landing regulating action.There is research display, at IVF by the ovum cycle, use PTX and vitamin E therapeutic alliance, can endometrium thickness be increased.Its mechanism is that PTX improves endometrium local T NF-α concentration, changes endometrial fibrotic condition, and still can not reach for use high dose estrogen the patient being satisfied with inner film thickness is a kind of available therapeutic scheme.But due to the case number of this research less (only having 18 examples), and also less about the research of this respect, result also needs large-scale clinical trial to confirm.
(5) granulocyte colony-stimulating factor (G-CSF)
G-CSF successfully plays an important role to human reproduction.It can improve plantation embryo, affect Decidual Macrophage, impact ovulation, ovarian function, granulocyte function, suppression autoimmune can, minimizing unknown cause habitual abortion rate.Research display, G-CSF promotes follicular development, increases the survival rate after embryo transfer, reduces abortion ratio.In uterine cavity, G-CSF perfusion is a kind of novel method that the intractable endometrium for the treatment of is thin at present.But the curative effect that this Therapeutic Method improves Embryo Implantation Rate in and pregnancy rate in auxiliary procreation technology needs to be observed further.
Above Therapeutic Method improves the pregnancy rate of endometrium thin property patient from improving endometrial blood flow or interior membrane-associated activity factor aspect, but very not clear and definite to the curative effect increasing endometrium thickness.
Theory of Chinese medical science is thought, the kidney being the origin of congenital constitution, main reproduction, and kidney and uterus are consistent, and woman's reproductive process is centered by " kidney ".The traditional Chinese medical science often adopts kidney tonifying, essence replenishing, benefiting QI and nourishing blood is invigorated blood circulation is main treatment, helps with the agent of the kidney warming, nourishing the liver, to reach increase endometrium thickness, increases uterine blood flow, promotes endometrium relevant biological activity factor expression, thus improves the object of uterine cavity lesion.And in treatment infertility, have accumulated rich experience.Therefore, employing Chinese medicine endometrium is thin has immeasurable bright prospects.
In prior art, with the pharmaceutical composition that Herba Epimedii, Fructus Ligustri Lucidi, Rhizoma Polygonati Odorati, Semen sojae atricolor, Flos Sophorae, Fructus Mori, Fructus Rubi, Radix Panacis Quinquefolii, Colla Corii Asini and Paecilomyces hepiali Chen et Dai Mycelia powder are primary raw material, prove that through animal function test there is the health care of enhancing immunity and increase bone density; Yet there are no so far and use it for treatment diminished ovarian reserve function and the thin report of endometrium.
Summary of the invention
The object of the invention is to propose with Herba Epimedii, Fructus Ligustri Lucidi, Rhizoma Polygonati Odorati, Semen sojae atricolor, Flos Sophorae, Fructus Mori, Fructus Rubi, Radix Panacis Quinquefolii, Colla Corii Asini and Paecilomyces hepiali Chen et Dai Mycelia powder the novelty teabag of pharmaceutical composition in the medicine for the preparation for the treatment of diminished ovarian reserve function and/or promotion Endometrium development being primary raw material.
For reaching this object, the present invention by the following technical solutions:
Pharmaceutical composition is in a purposes for the medicine for the preparation for the treatment of diminished ovarian reserve function and/or promotion Endometrium development, and described pharmaceutical composition is made up of Herba Epimedii, Fructus Ligustri Lucidi, Rhizoma Polygonati Odorati, Semen sojae atricolor, Flos Sophorae, Fructus Mori, Fructus Rubi, Radix Panacis Quinquefolii, Colla Corii Asini and Paecilomyces hepiali Chen et Dai Mycelia powder.
In above-mentioned application, as preferably, described pharmaceutical composition comprises: Herba Epimedii 15-35 weight portion, Fructus Ligustri Lucidi 10-20 weight portion, Rhizoma Polygonati Odorati 5-15 weight portion, Semen sojae atricolor 5-15 weight portion, Flos Sophorae 5-15 weight portion, Fructus Mori 5-15 weight portion, Fructus Rubi 5-15 weight portion, Radix Panacis Quinquefolii 1-5 weight portion, Colla Corii Asini 2-9 weight portion, Paecilomyces hepiali Chen et Dai Mycelia powder 1-5 weight portion.
More preferably, described pharmaceutical composition comprises: Herba Epimedii 16-32 weight portion, Fructus Ligustri Lucidi 12-18 weight portion, Rhizoma Polygonati Odorati 8-12 weight portion, Semen sojae atricolor 8-12 weight portion, Flos Sophorae 8-12 weight portion, Fructus Mori 8-12 weight portion, Fructus Rubi 8-12 weight portion, Radix Panacis Quinquefolii 2-4 weight portion, Colla Corii Asini 3-8 weight portion, Paecilomyces hepiali Chen et Dai Mycelia powder 2-4 weight portion.
Most preferably, described pharmaceutical composition comprises: Herba Epimedii 25 weight portion, Fructus Ligustri Lucidi 15 weight portion, Rhizoma Polygonati Odorati 10 weight portion, Semen sojae atricolor 10 weight portion, Flos Sophorae 10 weight portion, Fructus Mori 10 weight portion, Fructus Rubi 10 weight portion, Radix Panacis Quinquefolii 2.5 weight portion, Colla Corii Asini 5 weight portion, Paecilomyces hepiali Chen et Dai Mycelia powder 2.5 weight portion.
As preferably, described pharmaceutical composition also comprises one or more for improving or treat the medicine of accompanied symptoms; As when not affecting pharmaceutical composition effect, can be added one or more for improving or treat the Chinese medicine of accompanied symptoms, such as: distention and pain of breast before menstruation can add Radix Bupleuri, Fructus Gardeniae, Radix Scutellariae etc.; Vexed insomnia can add Cortex Albiziae, Caulis Polygoni Multiflori, LONGMU etc.
As preferably, described pharmaceutical composition also comprises the pharmaceutical carrier that pharmaceutically can accept to make preparation; Make the forms such as granule, oral liquid, tablet, capsule, pill as by pharmaceutical carrier, adopt existing commercial process all can realize.
The invention also discloses the method that described pharmaceutical composition can take any prior art, and add other composition any, decline for the preparation for the treatment of ovarian function and/or promote the medicine of Endometrium development.
As preferably, described promotion Endometrium development realizes by improving gynecological endocrine function and increasing endometrium thickness.
Beneficial effect of the present invention:
With the pharmaceutical composition that Herba Epimedii, Fructus Ligustri Lucidi, Rhizoma Polygonati Odorati, Semen sojae atricolor, Flos Sophorae, Fructus Mori, Fructus Rubi, Radix Panacis Quinquefolii, Colla Corii Asini and Paecilomyces hepiali Chen et Dai Mycelia powder are primary raw material, when being applied to the decline for the treatment of ovarian function, Ovary reserve can be improved, promote reproductive function, there is the effect of replenishing essence the kidney invigorating, nourishing blood for regulating menstruation, improve subjects reproductive atrophy and perimenopausal symptom; When being applied to promotion Endometrium development, gynecological endocrine function can being improved and increase endometrium thickness; For Chinese medicine preparation safely and effectively.
Detailed description of the invention
Technical scheme of the present invention is further illustrated below by detailed description of the invention.
Embodiment 1
The composition of pharmaceutical composition: Herba Epimedii 25 weight portion, Fructus Ligustri Lucidi 15 weight portion, Rhizoma Polygonati Odorati 10 weight portion, Semen sojae atricolor 10 weight portion, Flos Sophorae 10 weight portion, Fructus Mori 10 weight portion, Fructus Rubi 10 weight portion, Radix Panacis Quinquefolii 2.5 weight portion, Colla Corii Asini 5 weight portion, Paecilomyces hepiali Chen et Dai Mycelia powder 2.5 weight portion.
Embodiment 2
The composition of pharmaceutical composition: Herba Epimedii 16 weight portion, Fructus Ligustri Lucidi 12 weight portion, Rhizoma Polygonati Odorati 8 weight portion, Semen sojae atricolor 8 weight portion, Flos Sophorae 8 weight portion, Fructus Mori 8 weight portion, Fructus Rubi 8 weight portion, Radix Panacis Quinquefolii 2 weight portion, Colla Corii Asini 3 weight portion, Paecilomyces hepiali Chen et Dai Mycelia powder 2 weight portion.
Embodiment 3
The composition of pharmaceutical composition: Herba Epimedii 32 weight portion, Fructus Ligustri Lucidi 18 weight portion, Rhizoma Polygonati Odorati 12 weight portion, Semen sojae atricolor 12 weight portion, Flos Sophorae 12 weight portion, Fructus Mori 12 weight portion, Fructus Rubi 12 weight portion, Radix Panacis Quinquefolii 4 weight portion, Colla Corii Asini 8 weight portion, Paecilomyces hepiali Chen et Dai Mycelia powder 4 weight portion.
The pharmaceutical composition of above embodiment, when applying in the examples below, by the mode be decocted in water for oral dose after mixing by Chinese medicine composition.
The therapeutical effect of embodiment 4 pharmaceutical composition in diminished ovarian reserve function
Test method:
Ordinary circumstance:
Clinically select meet diminished ovarian reserve function patient 50 example, age 19-39 year, minimum 20 years old, maximum 39 years old, the course of disease the shortest year in June, the longest 4.5 years.Be divided into 2 groups at random, treatment group 25 example, age 34.47 scholar 5.72, the course of disease 3.02 scholar 0.42; Matched group 25 example, age 33.54 scholar 4.93, the course of disease 2.87 scholar 0.38; Two groups of ages course of disease zero difference (p>0.05), have comparability.
Diagnostic criteria:
(1) symptom: delayed menstrual cycle, or very few through measuring, or amenorrhea, or infertile.
(2) biochemistry detection: menstrual cycle the 3rd day extracting vein blood, measure serum hormone, 10mIU/ml<FSH (follicule-stimulating hormone (FSH)) <40mIU/ml, FSH/LH (lutropin) ratio >3.6, estradiol (E2) >80pg/ml, three possesses one, can point out diminished ovarian reserve function.
Inclusive criteria:
(1) above-mentioned diagnostic criteria is met.
(2) person that do not use medicine in first 1 month is treated.
Exclusion standard:
(1) hypomenorrhea, or delayed menstrual cycle, or amenorrhea, or infertile be because congenital reproductive development is abnormal, or the day after tomorrow organic disease and damage and the person of causing.
(2) hyperprolactinemia, polycystic ovarian syndrome.
(3) oneself know maybe can be suspected to have breast carcinoma or have breast carcinoma medical history person, known maybe can be suspected to have estrogen-dependent tumor, thrombotic disease, liver function deviant and psychotic.
(4) nearly 3 months acceptance hormone medicine therapists.
Therapeutic scheme:
Treatment group adopts the formula in above-mentioned three kinds of embodiments, and wherein embodiment 1 is 9 examples, and embodiment 2,3 is 8 examples.Give Chinese medicine compound of the present invention with being decocted in water for oral dose.
Matched group adopts hormone therapy, and oral estradiol valerate 1mg qd serve on 21d, within latter 5 days, adds medroxyprogestetone acetate 10mg qd, drug withdrawal 3-7 days menstrual onset, more the same medication treatment, continuous 3 menstrual cycle.
Observation index:
(1) clinical observation on the therapeutic effect
Criterion of therapeutical effect: with reference to People's Republic of China's traditional Chinese medicine industry standard---TCM Gynecology disease Standardization of diagnosis and curative effect.
1) drug withdrawal criterion of therapeutical effect in March:
Recovery from illness: recover normal through amount, menstrual period, cycle, more than 3 menstrual cycle can be maintained;
Take a turn for the better: though recover normal through amount, menstrual period, cycle, more than 3 menstrual cycle can not be maintained;
Invalid: symptom is without improvement.
2) drug withdrawal criterion of therapeutical effect in June:
Recovery from illness: recover normal through amount, menstrual period, cycle, more than 6 menstrual cycle can be maintained;
Take a turn for the better: though recover normal through amount, menstrual period, cycle, 3-5 menstrual cycle can be maintained;
Invalid: symptom is without improvement.
(2) gonadal hormone
Menstrual cycle the 3rd day extracting vein blood, measures serum and swashs rope, observes before treating and treats latter 3 months, 6 months serum FSHs, the change of FSH/LH ratio and E2.
(3) clinical symptoms
The improvement situation of the symptom such as hectic fever, hyperhidrosis, flush, emotional instability, insomnia, hyposexuality when 6 months before observing treatment and after drug withdrawal.
Result of study:
Drug withdrawal 3 months: matched group recovery from illness 20 example, take a turn for the better 3 examples, invalid 2 examples, total effective rate 92%; Treatment group recovery from illness 19 example, take a turn for the better 3 examples, invalid 3 examples, total effective rate 88%.Two groups of total effective rate there was no significant differences (P>0.05).
Drug withdrawal 6 months: matched group recovery from illness 5 example, take a turn for the better 8 examples, invalid 12 examples, total effective rate 52%; Treatment group recovery from illness 8 example, take a turn for the better 12 examples, invalid 5 examples, total effective rate 80%, and matched group and treatment group total effective rate have significant difference (P<0.05); The average effectiveness level of three embodiments is 79.7%, 4 examples of wherein fully recovering in embodiment 1 group of 9 example, and take a turn for the better 4 examples, invalid 1 example, effective percentage 89%; Recovery from illness 3 example in embodiment 2 group of 8 example, take a turn for the better 3 examples, invalid 2 examples, effective percentage 75%; Recovery from illness 1 example in embodiment 3 group of 8 example, take a turn for the better 5 examples, invalid 2 examples, effective percentage 75%.Therefore, in Chinese medicine composition of the present invention embodiment by weight ratio, with the proportioning of embodiment 1 for the best.
Compare between drug withdrawal 3 months: FSH, LH, E2 two groups, zero difference between group; More all statistical significance is had with before treatment.Drug withdrawal 6 months: treatment group FSH is starkly lower than matched group (P<0.0l), and E2 is apparently higher than matched group (P<0.0l).Show that Chinese medicine compound short term effect and property swash rope and substitute therapeutic equivalence, late result is better than matched group, the results are shown in Table 1(treatment group and matched group is mean scholar standard deviation).In addition have no apparent side effect in therapeutic process of the present invention, follow up a case by regular visits to the sickness rate not increasing the disease such as carcinoma of endometrium, breast carcinoma June.
Table 1, two groups of endocrine hormones compare
After two groups of climacteric sample symptom treatments, drug withdrawal no significant difference in March, after drug withdrawal June, the various symptom improvement rate for the treatment of group is obviously better than matched group, concrete outcome in table 2, before improving percentage rate=(before treatment-treatment after)/treatment.
Table 2, two groups of symptom improvement rates compare
The therapeutical effect that embodiment 5 pharmaceutical composition is thin to endometrium
Research is recruited:
Find endometrium thin property infertile patient (in the past at least one menstrual cycle take estradiol be more than or equal to 2mg/ days and around ovulation 1-2 days inner film thickness <0.8cm), 20 years old-45 years old age, voluntarily signature Informed Consent Form person 100 example.
Excluded cases standard:
1) organic disease such as bilateral salpingo obstruction causes infertile person;
2) spouse is male infertility patient;
3) the severe primary diseases such as cardiovascular and cerebrovascular vessel, liver, kidney and hemopoietic system are associated with;
4) do not meet inclusive criteria, not by regulation medication, the not congruent judgement person that affects the treatment of curative effect or data cannot be judged;
5) disturbance of intelligence, psychotic etc. mismatch therapist.
Grouping and administration:
The case of above-mentioned recruitment is divided into matched group and treatment group at random, often organizes each 50 examples; Two groups of infertile time limits and infertile type there was no significant difference, two groups of data have harmony.Matched group: take estradiol 2mg/d; Treatment group: while 2mg/d takes estradiol, gives the pharmaceutical composition of embodiment 1 in the usual way.
Testing index:
(1) measure hormonal readiness, be included in ovulation day and measure LH, E2 and VEGF, measure E2, P and VEGF in midluteal phase.
(2) ovulation day endometrium thickness and Endometrial blood flow situation (RI, PI) is measured in ovulation day B ultrasonic.Inner film thickness gets the 1.5cm-2cm place measurement forward and backward muscle layer in uterus and inner membrance interface distance under sagittal section distance palace.Ovulation day Endometrial blood flow detects: in uterus within the scope of 1-1.5cm at the bottom of film distance palace, colorful blood is the most obviously located, and shows its frequency spectrum, obtain blood flow parameter with pulse Doppler: pulsatility index (PI), drag index (RI).
Result of study is in table 3, table 4 and table 5.
Table 3, two groups of ovulation day blood E2, LH, VEGF compare
| Group | E2(pg/ml) | LH(mIU/ml) | VEGF(pg/ml) |
| Matched group | 225.36±113.24 | 17.32±6.23 | 101.63±46.81 |
| Treatment group | 360.82±86.31 | 26.32±5.26 | 212.00±92.63 |
Table 4, two groups of midluteal phase blood E2, P, VEGF compare
| Group | E2(pg/ml) | P(ng/ml) | VEGF(pg/ml) |
| Matched group | 202.36±87.31 | 11.32±6.83 | 175.63±67.81 |
| Treatment group | 360.93±107.18 | 20.36±6.28 | 252.07±68.03 |
Table 5, two groups of ovulation day endometrium thickness, Uterine Artery Blood Flows compare
| Group | Endometrium thickness (mm) | RI | PI |
| Matched group | 8.31±1.23 | 0.82±0.03 | 26.63±1.33 |
| Treatment group | 9.68±1.31 | 0.73±0.02 | 24.57±0.76 |
Table 3,4,5 displays, treatment group the blood serum E2 of ovulation day and midluteal phase, LH, VEGF level comparatively matched group raise; Treatment group ovulation day endometrium thickness comparatively matched group obviously thicken, and RI and the PI value of uterine artery comparatively matched group obviously reduce.
Applicant states, the present invention illustrates the present invention by above-described embodiment, but the present invention is not limited to above-mentioned, does not namely mean that the present invention must rely on above-mentioned could enforcement.Person of ordinary skill in the field should understand, any improvement in the present invention, to equivalence replacement and the interpolation of auxiliary element, the concrete way choice etc. of raw material selected by the present invention, all drops within protection scope of the present invention and open scope.
Claims (4)
1. pharmaceutical composition is in preparation by improving Uterine Artery Blood Flow and improve the blood serum E2 of midluteal phase, VEGF level to promote the purposes in the medicine of Endometrium development simultaneously, and the crude drug of described pharmaceutical composition consists of: Herba Epimedii 15-35 weight portion, Fructus Ligustri Lucidi 10-20 weight portion, Rhizoma Polygonati Odorati 5-15 weight portion, Semen sojae atricolor 5-15 weight portion, Flos Sophorae 5-15 weight portion, Fructus Mori 5-15 weight portion, Fructus Rubi 5-15 weight portion, Radix Panacis Quinquefolii 1-5 weight portion, Colla Corii Asini 2-9 weight portion, Paecilomyces hepiali Chen et Dai Mycelia powder 1-5 weight portion.
2. purposes according to claim 1, it is characterized in that, each raw material medicines in portions by weight proportioning is: Herba Epimedii 16-32 weight portion, Fructus Ligustri Lucidi 12-18 weight portion, Rhizoma Polygonati Odorati 8-12 weight portion, Semen sojae atricolor 8-12 weight portion, Flos Sophorae 8-12 weight portion, Fructus Mori 8-12 weight portion, Fructus Rubi 8-12 weight portion, Radix Panacis Quinquefolii 2-4 weight portion, Colla Corii Asini 3-8 weight portion, Paecilomyces hepiali Chen et Dai Mycelia powder 2-4 weight portion.
3. purposes according to claim 1, it is characterized in that, each raw material medicines in portions by weight proportioning is: Herba Epimedii 25 weight portion, Fructus Ligustri Lucidi 15 weight portion, Rhizoma Polygonati Odorati 10 weight portion, Semen sojae atricolor 10 weight portion, Flos Sophorae 10 weight portion, Fructus Mori 10 weight portion, Fructus Rubi 10 weight portion, Radix Panacis Quinquefolii 2.5 weight portion, Colla Corii Asini 5 weight portion, Paecilomyces hepiali Chen et Dai Mycelia powder 2.5 weight portion.
4. the purposes according to any one of claim 1-3, is characterized in that, described pharmaceutical composition also comprises the pharmaceutical carrier that pharmaceutically can accept.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310491415.9A CN103520487B (en) | 2013-10-18 | 2013-10-18 | A kind of purposes of pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310491415.9A CN103520487B (en) | 2013-10-18 | 2013-10-18 | A kind of purposes of pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103520487A CN103520487A (en) | 2014-01-22 |
| CN103520487B true CN103520487B (en) | 2015-10-28 |
Family
ID=49923074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310491415.9A Active CN103520487B (en) | 2013-10-18 | 2013-10-18 | A kind of purposes of pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103520487B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105920087A (en) * | 2016-06-13 | 2016-09-07 | 河南百消丹药业集团有限公司 | Pill for regulating gynecological disease caused by female endocrine dyscrasia and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101461894A (en) * | 2007-12-20 | 2009-06-24 | 汉生堂药业有限公司 | Medicament composition for treating female climacteric syndrome and delaying age |
-
2013
- 2013-10-18 CN CN201310491415.9A patent/CN103520487B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101461894A (en) * | 2007-12-20 | 2009-06-24 | 汉生堂药业有限公司 | Medicament composition for treating female climacteric syndrome and delaying age |
Non-Patent Citations (1)
| Title |
|---|
| 吕雪良.子宫内膜薄.《求子》.中医古籍出版社,2009,92. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103520487A (en) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258685B (en) | Compound traditional Chinese medicine for treating diminished ovarian reserve and application | |
| CN105031559A (en) | Traditional Chinese medicine for treating infertility due to polycystic ovarian syndromes | |
| Jiang et al. | Treatment of Chinese herbal medicine for female infertility | |
| Zhang et al. | Study on prevention effect of Zishen Yutai pill combined with progesterone for threatened abortion in rats | |
| Agorastos et al. | Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia | |
| CN103349766A (en) | Pharmaceutical composition for endless postpartum lochia | |
| CN109528980A (en) | A kind of Chinese medicine composition and its pharmacy application for treating Ovary reserve decline disease | |
| CN103520487B (en) | A kind of purposes of pharmaceutical composition | |
| CN104435238A (en) | Kidney-tonifying and bone-strengthening combined medicament and application thereof | |
| CN104523889B (en) | A kind of Chinese medicine preparation for the treatment of habitual abortion and preparation method thereof | |
| CN101332282B (en) | Traditional Chinese medicine composition for treating gynecologic diseases from kidney deficiency and genitals coldness, and its preparation method | |
| CN105943758B (en) | A kind of Chinese medicine composition that treating infertility and its application | |
| CN108498705A (en) | Vagina doubts glue bolt and preparation method thereof | |
| CN103919911A (en) | New use of pharmaceutical composition | |
| CN101152345B (en) | Traditional Chinese medicine preparation for treating female acyesis caused by ovulation obstacle | |
| Li et al. | Effect of Wenshentiaojing Decoction on Hormone Level and Follicular Number in Patients with Menstrual Disorder of Polycystic Ovary Syndrome | |
| Goyal et al. | Galactorrhea and amenorrhea in burn patients | |
| CN104042672B (en) | A kind of Chinese medicine compound prescription vaginal washing fluid and its preparation method and application | |
| CN111905022B (en) | Medicine for promoting ovulation and preparation method thereof | |
| CN107007652A (en) | Purposes of the Kangfuxin Liquid Combined with Chinese Herbal in the medicine for preparing treatment infertility | |
| CN105944033B (en) | Traditional Chinese medicine composition containing radix curcumae | |
| Wang et al. | Analysis of uterine artery and sex hormones in treating diminished ovarian reserve with tiaojing decoction | |
| Wang et al. | Clinical application of Bushen Jianpi Gutai Decoction in threatened abortion. Drug Comb Ther. 2022; 4 (1): 2. doi: 10.53388/DCT2022002 | |
| CN102114240B (en) | Application of medicament containing hirudin and cellosolve | |
| Yang et al. | The Effect of Letrozole Combined with HCG on Reproductive Hormone and HGF Level in Infertile Patients with PCOS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160314 Address after: 100101 Beijing City, Chaoyang District Road No. 13 Building 1 small 9 room 9006 Patentee after: Beijing Prudential Investment Limited by Share Ltd Address before: 438300 Hubei City, Huanggang province Jinqiao City Jinqiao Development Zone Jinqiao Road, Hubei Fenghuang Baiyun Mountain Pharmaceutical Co., Ltd. Patentee before: Hubei Fenghuang Baiyunshan Pharmaceutical Co., Ltd. |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140122 Assignee: Beijing Acting Pharmaceutical Biotechnology Co., Ltd. Assignor: Beijing Prudential Investment Limited by Share Ltd Contract record no.: 2017990000177 Denomination of invention: Application of drug composition Granted publication date: 20151028 License type: Common License Record date: 20170511 |
|
| EE01 | Entry into force of recordation of patent licensing contract |